TP53 mutations and SNPs as prognostic and predictive factors in patients with breast cancer (Review)
- 1 July 2018
- journal article
- review article
- Published by Spandidos Publications in Oncology Letters
- Vol. 16 (1), 34-40
- https://doi.org/10.3892/ol.2018.8627
Abstract
Tumor protein 53 (TP53) is a tumor suppressor gene that encodes tumor protein p53. Tumor protein p53 regulates the expression of target genes in response to cellular stress. Additionally, p53 participates in the regulation of cell cycle checkpoints, DNA repair and apoptosis. Mutations in the TP53 gene are associated with numerous types of human cancer, including breast cancer, sarcomas, brain tumors and adrenal cortical carcinomas. In breast cancer, TP53 mutations are a negative prognostic factor. Tumors with TP53 mutations are more likely to be aggressive (triple-negative or human epidermal growth factor receptor 2-positive breast cancer), and resistant to chemotherapy and radiotherapy. In addition to a well-known TP53 mutation, a number of single nucleotide polymorphisms have been systematically identified and evaluated in human populations. In the present article, the role of TP53 mutations and polymorphisms in clinical practice and breast cancer treatment has been described. Additionally, the existing data on TP53 polymorphisms in breast cancer as prognostic and predictive factors have been summarized. A literature search of these topics was performed through PubMed and abstracts of the main cancer congresses in recent years.Keywords
This publication has 65 references indexed in Scilit:
- The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysisNucleic Acids Research, 2012
- Dual Roles of MDM2 in the Regulation of p53: Ubiquitination Dependent and Ubiquitination Independent Mechanisms of MDM2 Repression of p53 ActivityGenes & Cancer, 2012
- Early onset HER2‐positive breast cancer is associated with germline TP53 mutationsCancer, 2011
- TP53 Status and Response to Treatment in Breast CancersJournal of Biomedicine and Biotechnology, 2011
- TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical UseCold Spring Harbor Perspectives in Biology, 2009
- Association of the germline TP53R337H mutation with breast cancer in southern BrazilBMC Cancer, 2008
- MDM2 SNP309 is associated with high grade node positive breast tumours and is in linkage disequilibrium with a novel MDM2 intron 1 polymorphismBMC Cancer, 2008
- Impact of mutant p53 functional properties onTP53mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 databaseHuman Mutation, 2007
- An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survivalProceedings of the National Academy of Sciences of the United States of America, 2005
- TP53Mutation is an Independent Prognostic Marker for Poor Outcome in Both Node-negative and Node-positive Breast CancerActa Oncologica, 2000